[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:b-cell-malignant-neoplasm":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":66,"states":67},"B-Cell Malignant Neoplasm",9,8,[8,16,22,29,35,41,47,53,59],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06634589","A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:18:13.438956Z","2026-07-05T05:32:16.763670Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05006716","A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies",[12],"2026-08-26T02:17:24.721169Z","2026-07-05T05:32:16.799692Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT04830137","A Study of NX-2127 in Adults With Relapsed\u002FRefractory B-cell Malignancies",[26],"Phase 1","2026-08-26T02:17:33.002248Z","2026-05-05T02:43:29.192735Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06590961","UBX-303061 in Subjects With Relapsed\u002FRefractory B-Cell Malignancies",[26],"2026-08-26T02:16:15.345907Z","2026-05-05T02:43:28.529005Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT05131022","A Study of NX-5948 in Adults With Relapsed\u002FRefractory B-cell Malignancies",[26],"2026-08-26T02:16:41.943926Z","2026-05-05T02:43:26.916657Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT05780034","A Study of AC676 for the Treatment of Relapsed\u002FRefractory B-Cell Malignancies",[26],"2026-08-26T02:18:48.678868Z","2026-05-05T02:43:26.739406Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT05643742","A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies",[12],"2026-08-26T02:17:12.307088Z","2026-05-05T02:43:26.685166Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT05602363","AS-1763 in Patients With Previously Treated CLL\u002FSLL or Non-Hodgkin Lymphoma",[26],"2026-08-26T02:17:36.611194Z","2026-05-05T02:35:31.742591Z",{"nct_id":60,"title":61,"phases":62,"status":63,"updated_at":64,"content_modified":65},"NCT05618028","Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets",[26],"ACTIVE_NOT_RECRUITING","2026-08-03T02:14:57.006298Z","2026-05-05T02:43:27.955165Z",[],[68,71,75,79,82,86,89,93,96,99,102,105,109,112],{"state":69,"count":5,"slug":70},"Texas","texas",{"state":72,"count":73,"slug":74},"Florida",7,"florida",{"state":76,"count":77,"slug":78},"California",6,"california",{"state":80,"count":77,"slug":81},"New York","new-york",{"state":83,"count":84,"slug":85},"Ohio",5,"ohio",{"state":87,"count":84,"slug":88},"Utah","utah",{"state":90,"count":91,"slug":92},"Colorado",4,"colorado",{"state":94,"count":91,"slug":95},"Illinois","illinois",{"state":97,"count":91,"slug":98},"Maryland","maryland",{"state":100,"count":91,"slug":101},"North Carolina","north-carolina",{"state":103,"count":91,"slug":104},"Washington","washington",{"state":106,"count":107,"slug":108},"Michigan",3,"michigan",{"state":110,"count":107,"slug":111},"Tennessee","tennessee",{"state":113,"count":107,"slug":114},"Wisconsin","wisconsin"]